Science
David Heredia
David Heredia/drdavidherediav.com

David Heredia: EGFRm NSCLC to SCLC Transformation – A Therapeutic Dead Zone

David Heredia, Head of Oncology Department at Punta Médica Hospital, shared a post on X:

“EGFRm NSCLC → SCLC transformation: still a therapeutic dead zone

Post-transformation treatment outcomes:

  • ORR: 25%
  • mPFS: 3.4 mo
  •  mOS: 9.9 mo

SCLC switch = poor prognosis despite platinum-etoposide. Need for better biomarkers and tailored therapies.”

Title: Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study

Authors: C. Catania, S.V. Liu, M. Garassino, A. Delmonte, V. Scotti, F. Cappuzzo, C. Genova, A. Russo, M. Russano, C. Bennati, I. Colantonio, S. Martini, M. Pino, F. Conforti, L. Pala, G. Muti, F. Citarella, E. Olmetto, A. Esposito, P. Cascetta, A. Di Lello, T. De Pas

You can read the Full Article on ESMO Open

David Heredia: EGFRm NSCLC to SCLC Transformation - A Therapeutic Dead Zone

More posts featuring David Heredia.

A. Delmonte A. Di Lello A. Esposito A. Russo C. Bennati C. Catania C. Genova cancer David Heredia E. Olmetto F. Cappuzzo F. Citarella F. Conforti G. Muti I. Colantonio L. Pala Lung cancer M. Garassino M. Pino M. Russano NSCLC OncoDaily Oncology P. Cascetta S. Martini S. V. Liu SCLC T. De Pas V. Scotti